https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53799 Wed 28 Feb 2024 15:24:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50855 Wed 09 Aug 2023 09:52:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47205 Wed 06 Mar 2024 14:59:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54622 Wed 06 Mar 2024 10:53:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54624 Wed 06 Mar 2024 10:53:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54623 Wed 06 Mar 2024 10:51:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49079 Wed 03 May 2023 16:14:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50402 Tue 25 Jul 2023 14:14:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55702 Tue 18 Jun 2024 12:40:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53499 Thu 30 Nov 2023 15:57:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45364 Thu 27 Oct 2022 15:35:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45138 Thu 27 Oct 2022 14:07:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48870 Thu 13 Apr 2023 12:48:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49876 3 mg/L), and depression. In both trials, TT treatment led to a large, significant improvement in HRQOL compared with usual care (Cohen's d = 1.19; P < .001). Receiving a statin for systemic inflammation and oral corticosteroid for eosinophilic airway inflammation was associated with the largest HRQOL improvements. Treatments for exercise intolerance, anxiety, and obesity were associated with smaller improvements in HRQOL. Conclusions: This study contributes to identifying clinically impactful TTs by showing that TTs across pulmonary, extrapulmonary, and behavioral domains were associated with HRQOL impairment and treatment response.]]> Thu 08 Jun 2023 15:21:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46276 Mon 14 Nov 2022 15:31:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44178 Mon 10 Oct 2022 10:20:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55058 Mon 08 Apr 2024 09:43:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53110 2-agonist. This study shows that, in response to the limitation of a stepwise approach to therapy, treatable traits is a new strategy where patients are individually assessed for a specified set of treatable problems, and an individualized treatment program is developed and implemented based on this multidimensional assessment, especially for difficult-to-treat asthma.]]> Fri 17 Nov 2023 11:25:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37892 Fri 01 Apr 2022 09:25:28 AEDT ]]>